| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3287049 | Digestive and Liver Disease Supplements | 2009 | 4 Pages |
Abstract
The majority of interferons available for therapeutic use are derived from the prokaryote E. coli. A new recombinant human interferon α2a (IFN-α2a; Reiferon®) has been derived from the yeast Hansenula polymorpha – a eukaryotic expression system. Safety and efficacy for this drug was tested in patients with chronic hepatitis C in Egypt. The unmodified yeast-derived IFN-α2a is the basis for a newly developed PEGylated IFN-α2a (Reiferon Retard®) which will be described in the following.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
